{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:06:02Z","timestamp":1753520762719},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1097\/md.0000000000010294","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T16:57:12Z","timestamp":1522861032000},"page":"e0294","source":"Crossref","is-referenced-by-count":7,"title":["Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide"],"prefix":"10.1097","volume":"97","author":[{"given":"Binbin","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qitian","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-28-20210309","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2012.064485","article-title":"Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"R2-28-20210309","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"key":"R3-28-20210309","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2010.202","article-title":"Mixed-phenotype acute leukemia: historical overview and a new definition","volume":"24","author":"Weinberg","year":"2010","journal-title":"Leukemia"},{"key":"R4-28-20210309","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"R5-28-20210309","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12185-011-0953-1","article-title":"Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and\/or BCR-ABL positive in adult","volume":"94","author":"Wang","year":"2011","journal-title":"Int J Hematol"},{"key":"R6-28-20210309","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-012-1026-9","article-title":"Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph\u200a+\u200aCML or relapsed\/refractory Ph\u200a+\u200aALL: a 36-month analysis of a phase I and II study","volume":"95","author":"Usuki","year":"2012","journal-title":"Int J Hematol"},{"key":"R7-28-20210309","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Foa","year":"2011","journal-title":"Blood"},{"key":"R8-28-20210309","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CMAR.S81310","article-title":"Expanding role of lenalidomide in hematologic malignancies","volume":"7","author":"Ghosh","year":"2015","journal-title":"Cancer Manage Res"},{"key":"R9-28-20210309","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"R10-28-20210309","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3324\/haematol.2012.076414","article-title":"Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia","volume":"98","author":"Pollyea","year":"2013","journal-title":"Haematologica"},{"key":"R11-28-20210309","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2013.05.011","article-title":"Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)","volume":"37","author":"Attar","year":"2013","journal-title":"Leuk Res"},{"key":"R12-28-20210309","first-page":"70","article-title":"Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities","volume":"2","author":"Dennis","year":"2013","journal-title":"Leuk Res Rep"},{"key":"R13-28-20210309","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/leu.2013.26","article-title":"Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study","volume":"27","author":"Platzbecker","year":"2013","journal-title":"Leukemia"},{"key":"R14-28-20210309","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/07357900500283101","article-title":"Immunomodulatory drugs","volume":"23","author":"Crane","year":"2005","journal-title":"Cancer Invest"},{"key":"R15-28-20210309","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T18:55:34Z","timestamp":1720205734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201804060-00028"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":15,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010294","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}